465 related articles for article (PubMed ID: 8080242)
1. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
[TBL] [Abstract][Full Text] [Related]
2. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis.
Jesse S; Kassubek J; Müller HP; Ludolph AC; Unrath A
BMC Neurol; 2012 Dec; 12():163. PubMed ID: 23273141
[TBL] [Abstract][Full Text] [Related]
3. Lipid pathway alterations in Parkinson's disease primary visual cortex.
Cheng D; Jenner AM; Shui G; Cheong WF; Mitchell TW; Nealon JR; Kim WS; McCann H; Wenk MR; Halliday GM; Garner B
PLoS One; 2011 Feb; 6(2):e17299. PubMed ID: 21387008
[TBL] [Abstract][Full Text] [Related]
4. The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders.
Correa BHM; Moreira CR; Hildebrand ME; Vieira LB
Curr Neuropharmacol; 2023; 21(2):183-201. PubMed ID: 35339179
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.
Bonsi P; Cuomo D; Martella G; Sciamanna G; Tolu M; Calabresi P; Bernardi G; Pisani A
Curr Neuropharmacol; 2006 Jan; 4(1):69-75. PubMed ID: 18615133
[TBL] [Abstract][Full Text] [Related]
6. A pH-eQTL Interaction at the
Patel S; Howard D; French L
Front Aging Neurosci; 2021; 13():690632. PubMed ID: 34305570
[TBL] [Abstract][Full Text] [Related]
7. Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson's Disease Dementia.
Scholefield M; Church SJ; Xu J; Patassini S; Hooper NM; Unwin RD; Cooper GJS
Metabolites; 2021 Aug; 11(9):. PubMed ID: 34564384
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system uptake of intranasal glutathione in Parkinson's disease.
Mischley LK; Conley KE; Shankland EG; Kavanagh TJ; Rosenfeld ME; Duda JE; White CC; Wilbur TK; De La Torre PU; Padowski JM
NPJ Parkinsons Dis; 2016; 2():16002. PubMed ID: 28725693
[TBL] [Abstract][Full Text] [Related]
9. Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop.
Stephenson D; Belfiore-Oshan R; Karten Y; Keavney J; Kwok DK; Martinez T; Montminy J; Müller MLTM; Romero K; Sivakumaran S
Neurotherapeutics; 2023 Oct; 20(6):1682-1691. PubMed ID: 37823970
[TBL] [Abstract][Full Text] [Related]
10. Eye movement abnormalities in movement disorders.
Lal V; Truong D
Clin Park Relat Disord; 2019; 1():54-63. PubMed ID: 34316601
[TBL] [Abstract][Full Text] [Related]
11. Silent struggles: Parkinson's disease with multiple system atrophy.
Abd Malek K
Malays Fam Physician; 2024; 19():14. PubMed ID: 38623416
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders".
Mol Ther; 2016 Apr; 24(4):843. PubMed ID: 27081723
[No Abstract] [Full Text] [Related]
13. Retraction Notice to: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.
Javed H; Menon SA; Al-Mansoori KM; Al-Wandi A; Majbour NK; Ardah MT; Varghese S; Vaikath NN; Haque ME; Azzouz M; El-Agnaf OM
Mol Ther; 2024 Apr; ():. PubMed ID: 38608700
[No Abstract] [Full Text] [Related]
14. Retraction Notice to: Corrigendum to "Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders".
Javed H; Menon SA; Al-Mansoori KM; Al-Wandi A; Majbour NK; Ardah MT; Varghese S; Vaikath NN; Haque ME; Azzouz M; El-Agnaf OM
Mol Ther; 2024 Apr; ():. PubMed ID: 38608701
[No Abstract] [Full Text] [Related]
15. Reduced intravenous glutathione in the treatment of early Parkinson's disease.
Sechi G; Deledda MG; Bua G; Satta WM; Deiana GA; Pes GM; Rosati G
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1159-70. PubMed ID: 8938817
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
17. Glutathione-related enzymes in brain in Parkinson's disease.
Sian J; Dexter DT; Lees AJ; Daniel S; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):356-61. PubMed ID: 8080243
[TBL] [Abstract][Full Text] [Related]
18. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
Polymeropoulos MH; Lavedan C; Leroy E; Ide SE; Dehejia A; Dutra A; Pike B; Root H; Rubenstein J; Boyer R; Stenroos ES; Chandrasekharappa S; Athanassiadou A; Papapetropoulos T; Johnson WG; Lazzarini AM; Duvoisin RC; Di Iorio G; Golbe LI; Nussbaum RL
Science; 1997 Jun; 276(5321):2045-7. PubMed ID: 9197268
[TBL] [Abstract][Full Text] [Related]
19. Glutamate and Parkinson's disease.
Blandini F; Porter RH; Greenamyre JT
Mol Neurobiol; 1996 Feb; 12(1):73-94. PubMed ID: 8732541
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
